Time trends in statin utilisation and coronary mortality in Western European countries

Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort

(2015) Henna Cederberg et al.   DIABETOLOGIA

Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults

(2015) Ishak Mansi et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA)

(2015) Catriona Murphy et al.   BMJ Open

Rosuvastatin: winner in the statin wars, patients' health notwithstanding

(2015) S. Wolfe   BMJ-British Medical Journal

Rosuvastatin: winner in the statin wars, patients' health notwithstanding

(2015) S. Wolfe   BMJ-British Medical Journal

The impact of Regional co-payment and National reimbursement criteria on statins use in Italy: an interrupted time-series analysis

(2014) Gianfranco Damiani et al.   BMC HEALTH SERVICES RESEARCH

Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review

(2014) Mary A. De Vera et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cardiovascular disease in Europe 2014: epidemiological update

(2014) Melanie Nichols et al.   EUROPEAN HEART JOURNAL

Family history of cardiovascular disease and influence on statin therapy persistence

(2014) Anna Citarella et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Systematic review of factors affecting pharmaceutical expenditures

(2014) Mohamed Awad Mousnad et al.   HEALTH POLICY

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications

(2014) Brian Godman et al.   Frontiers in Pharmacology

Starting statins for primary prevention of cardiovascular disease

(2013) Hugh Tunstall-Pedoe   HEART

The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?

(2013) Tjeerd-Pieter van Staa et al.   HEART

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials

(2013) Huseyin Naci et al.   European Journal of Preventive Cardiology

The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium

(2013) Jessica Fraeyman et al.   Expert Review of Pharmacoeconomics & Outcomes Research

General Practitioners’ coronary risk estimates, decisions to start lipid-lowering treatment, gender and length of clinical experience: their interactions in primary prevention

(2013) Federico Vancheri et al.   Primary Health Care Research and Development

Proportion and Risk Indicators of Nonadherence to Statin Therapy: A Meta-analysis

(2012) Mark Lemstra et al.   CANADIAN JOURNAL OF CARDIOLOGY

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

(2012) et al.   EUROPEAN HEART JOURNAL

Statins for all?

(2012) M. McCartney   BMJ-British Medical Journal

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications

(2012) Menno van Woerkom et al.   Journal of Comparative Effectiveness Research

Soft regulations in pharmaceutical policy making

(2012) Björn Wettermark et al.   Applied Health Economics and Health Policy

Proportion of the Decline in Cardiovascular Mortality Disease due to Prevention Versus Treatment: Public Health Versus Clinical Care

(2011) Earl S. Ford et al.   Annual Review of Public Health

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study

(2011) J. R. Banegas et al.   EUROPEAN HEART JOURNAL

Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden

(2011) Billie Pettersson et al.   HEALTH POLICY

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

(2011) Salim Yusuf et al.   LANCET

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

(2011) Hans-Georg Eichler et al.   NATURE REVIEWS DRUG DISCOVERY

Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy

(2011) Helle Wallach Kildemoes et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications

(2011) Brian Godman et al.   Frontiers in Pharmacology

Statin prescription in men and women at cardiovascular risk: to whom and when?

(2010) Jasper J Brugts et al.   CURRENT OPINION IN CARDIOLOGY

Association of Temporal Trends in Risk Factors and Treatment Uptake With Coronary Heart Disease Mortality, 1994-2005

(2010) Harindra C. Wijeysundera   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of Restricted Reimbursement on the Use of Statins in Finland

(2010) Jaana E. Martikainen et al.   MEDICAL CARE

Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials

(2010) E. J. Mills et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Statin Adverse Effects

(2009) Beatrice A Golomb et al.   American Journal of Cardiovascular Drugs

Explaining the Decrease in Coronary Heart Disease Mortality in Italy Between 1980 and 2000

(2009) Luigi Palmieri et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Cardiovascular risk factor trends and options for reducing future coronary heart disease mortality in the United States of America

(2009) Simon Capewell et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002

(2009) Lena Björck et al.   EUROPEAN HEART JOURNAL

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

(2009) Kornelia Kotseva et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Can individuals with a significant risk for cardiovascular disease be adequately identified by combination of several risk factors? Modelling study based on the Norwegian HUNT 2 population

(2009) Halfdan Petursson et al.   JOURNAL OF EVALUATION IN CLINICAL PRACTICE

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

(2009) Kornelia Kotseva et al.   LANCET

Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model

(2008) Helle Wallach Kildemoes et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education

(2008) Randi Selmer et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

What explains declining coronary mortality? Lessons and warnings

(2008) S. Capewell et al.   HEART